NVIDIA took a strategic stake in suppliers and signed agreements that secure optics and manufacturing capacity. That improves NVIDIA's access to the parts and capacity it needs to build larger AI systems.
NVIDIA's stake and strategic agreement with Coherent gives it direct access to optics and manufacturing capacity. That helps NVIDIA build larger, denser AI systems. The deal's purchase commitments and product access drive the bullish read, despite the general risk that big firms can misstep on investments.
Merck owns several small drug-platform companies and uses its scientists and regulatory teams to vet investments. That expertise increases the chance these holdings add value to Merck's business.
Coherent issued shares to NVIDIA, raised cash, and signed a multiyear strategic agreement with purchase commitments. Those commitments and funding strengthen Coherent's role supplying optics for AI data centers, though it still faces cyclical markets and heavy investment needs.
NVIDIA is listed as an owner of CoreWeave and CoreWeave rents computing power that aligns with NVIDIA's needs. The article gives no financial or contractual details, so it does not change how I read CoreWeave today.
The article notes Merck owns Alector but provides no deal terms or commitments. That mention alone does not change how I read Alector's business prospects.
Follow NVIDIA (NVDA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVDA